Alzamend Neuro (ALZN) Expected to Release Earnings on Wednesday

Alzamend Neuro (NASDAQ:ALZN) is projected to release its Q1 2027 results before the market opens on Wednesday, September 9th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Investors may visit the the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Wednesday, September 16, 2026 at 8:00 AM ET.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, analysts expect Alzamend Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alzamend Neuro Stock Performance

NASDAQ ALZN opened at $1.66 on Monday. The business has a fifty day moving average price of $1.39 and a 200 day moving average price of $1.37. Alzamend Neuro has a one year low of $0.84 and a one year high of $2.68. The company has a market cap of $8.02 million, a P/E ratio of -0.57 and a beta of 0.23.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC grew its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,506 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned approximately 0.72% of Alzamend Neuro worth $50,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 49.61% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.